MIST Milestone Pharmaceuticals Inc
4,589
$1.71
$0.04
(2.29%)
| Watchers | 4,589 |
| 52-Wk Low | $1.33 |
| 52-Wk High | $4.14 |
| Market Cap | $91.08M |
| Volume | 87,944.00 |
| 52-Wk High | $4.14 |
| 52-Wk Low | $1.33 |
Milestone Pharmaceuticals Upgraded to Buy: Here's What You Should KnowBenzinga • 11 days ago
Milestone Pharmaceuticals (NASDAQ: MIST) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings...
Share to Feed
MONTREAL and CHARLOTTE, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will deliver a company...
MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of...
MONTREAL and CHARLOTTE, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of...
Milestone Pharmaceuticals (MIST) has released an update. Milestone Pharmaceuticals has announced the resubmission of its New Drug Application to th...
Milestone Pharmaceuticals (NASDAQ:MIST Get Free Report)s stock had its buy rating restated by research analysts at HC Wainwright in a research note issued on Friday...
- On track to resubmit NDA for etripamil in PSVT early 2Q 2024 - Recent financing extends cash runway into 2026 - FDA reiterated prior guidance on regulatory pathway for AFib-RVR, End of Phase 2...
MONTREAL andCHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. ( Milestone ) (Nasdaq: MIST), a biopharmaceutical company focused on the development and...
MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a corporate...